HRP20010285A2 - Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor - Google Patents

Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Info

Publication number
HRP20010285A2
HRP20010285A2 HR20010285A HRP20010285A HRP20010285A2 HR P20010285 A2 HRP20010285 A2 HR P20010285A2 HR 20010285 A HR20010285 A HR 20010285A HR P20010285 A HRP20010285 A HR P20010285A HR P20010285 A2 HRP20010285 A2 HR P20010285A2
Authority
HR
Croatia
Prior art keywords
inhibitor
controlled
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
HR20010285A
Other languages
English (en)
Inventor
Elizabeth King
Ross James Macrae
Original Assignee
Pfizer Res And Dev Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010285(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Res And Dev Company filed Critical Pfizer Res And Dev Company
Publication of HRP20010285A2 publication Critical patent/HRP20010285A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20010285A 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor HRP20010285A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations
PCT/IB1999/001619 WO2000024383A1 (en) 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Publications (1)

Publication Number Publication Date
HRP20010285A2 true HRP20010285A2 (en) 2002-06-30

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010285A HRP20010285A2 (en) 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Country Status (44)

Country Link
US (1) US6964780B1 (de)
EP (1) EP1123088B1 (de)
JP (1) JP2002528408A (de)
KR (1) KR20010075659A (de)
CN (1) CN1324233A (de)
AP (1) AP2001002125A0 (de)
AT (1) ATE340562T1 (de)
AU (1) AU756509B2 (de)
BG (1) BG65323B1 (de)
BR (1) BR9914718A (de)
CA (1) CA2348086C (de)
CO (1) CO5160262A1 (de)
CR (1) CR6326A (de)
CY (1) CY1106239T1 (de)
CZ (1) CZ20011427A3 (de)
DE (1) DE69933383T2 (de)
DK (1) DK1123088T3 (de)
DZ (1) DZ2923A1 (de)
EA (1) EA004068B1 (de)
EE (1) EE200100235A (de)
ES (1) ES2272082T3 (de)
GT (1) GT199900184A (de)
HK (1) HK1041818A1 (de)
HR (1) HRP20010285A2 (de)
HU (1) HUP0104318A3 (de)
ID (1) ID28232A (de)
IL (1) IL141764A (de)
IS (1) IS5865A (de)
MA (1) MA26700A1 (de)
MX (1) MXPA01004011A (de)
MY (1) MY130727A (de)
NO (1) NO20011933L (de)
NZ (1) NZ510275A (de)
OA (1) OA11664A (de)
PA (1) PA8484301A1 (de)
PE (1) PE20001286A1 (de)
PL (1) PL195789B1 (de)
PT (1) PT1123088E (de)
SK (1) SK286473B6 (de)
TR (1) TR200101103T2 (de)
TW (1) TW577756B (de)
UA (1) UA67802C2 (de)
UY (1) UY25765A1 (de)
WO (1) WO2000024383A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EP1126826B3 (de) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
EP2054041A2 (de) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulierungen von flibanserin und herstellungsverfahren dafür
IL197129A (en) 2006-08-25 2014-08-31 Boehringer Ingelheim Int Controlled release system and method for production
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
EP2167057A1 (de) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde-hemmer zur behandlung von gehörschäden
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
US20110244050A1 (en) * 2008-12-12 2011-10-06 Siegfried Rhein S.A. De C.V. Pulsed-release sildenafil composition and method for preparing said composition
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
KR102158948B1 (ko) 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
AU2976897A (en) * 1996-06-18 1998-01-07 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
PL334439A1 (en) * 1997-01-06 2000-02-28 Pfizer Rapidly liberating and taste masking pharmaceutical administration form
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
NO20011933D0 (no) 2001-04-19
EE200100235A (et) 2002-08-15
EA200100298A1 (ru) 2001-08-27
SK286473B6 (sk) 2008-11-06
ATE340562T1 (de) 2006-10-15
PL195789B1 (pl) 2007-10-31
ID28232A (id) 2001-05-10
AU5878799A (en) 2000-05-15
PA8484301A1 (es) 2000-09-29
TW577756B (en) 2004-03-01
BR9914718A (pt) 2001-07-10
CY1106239T1 (el) 2011-06-08
PE20001286A1 (es) 2000-11-22
DK1123088T3 (da) 2007-01-02
TR200101103T2 (tr) 2001-09-21
CN1324233A (zh) 2001-11-28
DE69933383D1 (de) 2006-11-09
NZ510275A (en) 2003-07-25
CO5160262A1 (es) 2002-05-30
BG105465A (bg) 2001-12-29
NO20011933L (no) 2001-06-25
CA2348086A1 (en) 2000-05-04
UA67802C2 (uk) 2004-07-15
US6964780B1 (en) 2005-11-15
AU756509B2 (en) 2003-01-16
MA26700A1 (fr) 2004-12-20
IL141764A (en) 2008-06-05
CR6326A (es) 2004-02-23
KR20010075659A (ko) 2001-08-09
PT1123088E (pt) 2007-01-31
MXPA01004011A (es) 2003-03-10
UY25765A1 (es) 2001-08-27
PL347476A1 (en) 2002-04-08
GT199900184A (es) 2001-04-14
EP1123088A1 (de) 2001-08-16
JP2002528408A (ja) 2002-09-03
EA004068B1 (ru) 2003-12-25
IL141764A0 (en) 2002-03-10
OA11664A (en) 2005-01-07
AP2001002125A0 (en) 2001-04-04
HUP0104318A2 (hu) 2002-03-28
CA2348086C (en) 2007-01-23
WO2000024383A1 (en) 2000-05-04
HK1041818A1 (zh) 2002-07-26
CZ20011427A3 (cs) 2001-10-17
MY130727A (en) 2007-07-31
DE69933383T2 (de) 2007-02-01
SK5192001A3 (en) 2002-09-10
BG65323B1 (bg) 2008-02-29
IS5865A (is) 2001-02-27
ES2272082T3 (es) 2007-04-16
HUP0104318A3 (en) 2003-12-29
DZ2923A1 (fr) 2004-03-01
EP1123088B1 (de) 2006-09-27

Similar Documents

Publication Publication Date Title
HRP20010285A2 (en) Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor
IL110014A0 (en) Solid controlled-release oral dosage forms
HUP0002469A3 (en) Solid thermoformable controlled-release pharmaceutical composition
ZA983402B (en) Bioadhesive tablets
GB9713149D0 (en) Pharmaceutical formulations
SG79255A1 (en) Pharmaceutical formulations
EP0956854A4 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
ZA981622B (en) Radiation-curable cyanoacrylate-containing compositions
PL334959A1 (en) Film-coated oxacarbazepin tablets
GB9700504D0 (en) Pharmaceutical compounds
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
PL339461A1 (en) Orally administered compositions containing levosimendane
GB9716244D0 (en) Pharmaceutical compounds
EP1003495A4 (de) Pharmazeutische verbindungen
GB0110612D0 (en) Controlled-release garlic formulations
IL131917A (en) Pharmaceutical compositions containing lamivudine
HUP9902458A3 (en) Slow-release pharmaceutical formulations containing mizolastin
GB9826000D0 (en) Tablets
IL128107A0 (en) Pharmaceutical compositions containing a pkc inhibitor
GB9700895D0 (en) Pharmaceutical compounds
IL131039A0 (en) Oxacarbazepine film-coated tablets
SI0966287T1 (en) Oxacarbazepine film-coated tablets
SI0906101T1 (en) Slow-release pharmaceutical formulations containing mizolastin
GB9823192D0 (en) Pharmaceutical formulations
GB9816558D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn